Skip to main content
SpringerLink
Log in

Menopausal Hormone Therapy: A Safety Perspective

  • Chapter
  • First Online:
Medicines For Women

Abstract

Menopausal hormone therapy (MHT) is an effective treatment for menopausal symptoms and reduces the risk of fracture. However, use results in a net increase in the risk of certain potentially life-threatening conditions including breast cancer, stroke, ovarian cancer and venous thromboembolism, and, additionally, use of oestrogen-only MHT increases the risk of endometrial cancer in women with a uterus. Overall risks increase with increasing duration of use and with age and are greater for oestrogen-progestagen MHT than for oestrogen-only MHT.

Increasing availability and consistency of data on the risks and benefits of MHT has been accompanied by agreement between key drug regulatory authorities that use should be targeted for moderate to severe menopausal symptoms only, and not for the prevention of disease. Key strategies for minimising MHT-associated risks are consistent with advice from drug regulatory agencies and include the following: MHT should be used for the short term treatment of menopausal symptoms (e.g. hot flushes, night sweats, vaginal dryness) only; women considering use of MHT should be informed of its risks and benefits; MHT should not be used for the prevention of disease, or (e.g. in Europe and Australia) as first line treatment for osteoporosis; MHT should be used for as short a period of time as possible and the need for continuing use should be reviewed six-monthly or annually. Preferential use of oestrogen-only MHT and transdermal oestrogen-only MHT, including judicious use in women with a uterus, is also likely to reduce MHT-associated risks, compared to use of oestrogen-progestagen MHT and oral MHT.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Australian Drug Evaluation Committee (2004) ADEC summary statement on HRT. Australian Government Department of Health and Ageing, Therapeutic Goods Administration, Canberra

    Google Scholar 

  • Banks E, Canfell K (2009) Invited commentary: hormone therapy risks and benefits – the women’s health initiative findings and the postmenopausal estrogen timing hypothesis. Am J Epidemiol 174:24–28

    Article  Google Scholar 

  • Banks E, Beral V, Reeves G, Balkwill A, Barnes I, for the Million Women Study Collaborators (2004a) Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 291:2212–2220

    Article  CAS  PubMed  Google Scholar 

  • Banks E, Beral V, Reeves G, for the Million Women Study Collaborators (2004b) Published results on breast cancer and hormone replacement therapy in the Million Women Study are correct. Climacteric 7:415–416

    Article  CAS  PubMed  Google Scholar 

  • Banks E, Reeves G, Evans S (2004c) Disease incidence associated with long-term use of hormone replacement therapy. In: Critchley HOD, Beral V, Gebbie A (eds) Menopause and hormone replacement, Proceedings of the forty seventh study group of the Royal College of Obstetricians and Gynaecologists. Royal College of Obstetricians and Gynaecologists, London, pp 241–254

    Google Scholar 

  • Barrett-Connor E, Stuenkel CA (2001) Hormone replacement therapy (HRT) – risks and benefits. Int J Epidemiol 30(3):423–426

    Article  CAS  PubMed  Google Scholar 

  • Beral V, Banks E, Reeves G, Appleby PN (1999) Use of HRT and the subsequent risk of cancer. J Epidemiol Biostatistics 4:191–215

    CAS  Google Scholar 

  • Brunner RL, Gass M, Aragaki AK, Hays J, Granek IA, Woods NF, Mason E, Brzyski RG, Ockene JK, Assaf AR, LaCroix AZ, Matthews KA, Wallace R, Women’s Health Investigators (2005) Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy. Arch Intern Med 165:1976–1986

    Article  CAS  PubMed  Google Scholar 

  • Canfell K, Banks E, Moa A, Beral V (2008) Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 188:641–644

    PubMed  Google Scholar 

  • Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick M, Wactawski-Wende J, Watts NB, Investigators ftWsHI (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative Randomised Trial. JAMA 290:1729–1738

    Article  CAS  PubMed  Google Scholar 

  • Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350:1047–1059

    Article  Google Scholar 

  • Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, Brzyski RG, LaCroix AZ, Granek IA, Valanis BG, Investigators ftWsHI (2003) Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348:1839–1854

    Article  CAS  PubMed  Google Scholar 

  • Hendrix S, Cochrane B, Nygaard I, Handa VL, Barnabei V, Iglesia C, Aragaki AK, Naughton M, Wallace R, McNeeley SG (2005) Effects of estrogen with and without progestin on urinary incontinence. JAMA 293:935–948

    Article  CAS  PubMed  Google Scholar 

  • Holmberg L, Anderson H (2004) HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet 363:453–455

    Article  CAS  PubMed  Google Scholar 

  • International Agency for Research on Cancer (1999) Hormonal contraception and post-menopausal hormonal therapy, vol 72. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. International Agency for Research on Cancer, Lyon

    Google Scholar 

  • Liu B, Beral V, Balkwill A, Green J, Sweetland S, Reeves G, for the Million Women Study Collaborators (2008) Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ 337:a3.86. doi:310.1136/bmj.a1386

    Google Scholar 

  • MacLennan A, Broadbent J, Lester S, Moore V (2004) Oral oestrogen and combined oestrogen/progestagen therapy versus placebo for hot flushes. Cochrane Database Syst Rev (4):CD002978. doi:002910.001002/14651858.CD14002978.pub14651852

    Google Scholar 

  • Medicines and Healthcare products Regulatory Agency (2007) UK public assessment report. Hormone-replacement therapy: safety update. MHRA. http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con2032228.pdf. Accessed January 2009

  • Million Women Study Collaborators (2002) Patterns of use of hormone replacement therapy in one million women in Britain, 1996–2000. Br J Obstet Gynaecol 109:1319–1330

    Article  Google Scholar 

  • Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427

    Article  Google Scholar 

  • Million Women Study Collaborators (2005) Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365:1543–1551

    Article  Google Scholar 

  • Million Women Study Collaborators (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369:1703–1710

    Article  Google Scholar 

  • Olie V, Canonico M, Scarabin PY (2010) Risk of venous thrombosis with oral vs. transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol 17:457–463

    Article  CAS  PubMed  Google Scholar 

  • Prentice R, Manson JE, Langer R, Anderson G, Pettinger M, Jackson R, Johnson K, Kuller LH, Lane D, Wactawski-Wende J, Brzyski RG, Ockene JK, Sarto G, Rossouw J (2009) Benefits and risks of postmenopausal hormone therapy when initiated soon after then menopause. Am J Epidemiol 170:12–23

    Article  PubMed Central  PubMed  Google Scholar 

  • Ravdin PM, Cronin KA, Howlander N, Berg CD, Chlebowski R, Fueur EJ, Edwards BK, Berry DA (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670–1674

    Article  CAS  PubMed  Google Scholar 

  • Simon JA, Hunninghake D, Agarwel SK, Lin F, Cauley JA, Ireland CC, Pickar JH (2001) Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. Ann Intern Med 135:493–501

    Article  CAS  PubMed  Google Scholar 

  • Sweetland S, Beral V, Balkwill A, Liu B, Benson VS, Canonico M, Green J, Reeves G, Collaborators MWS (2012) Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost 10:2277–2286

    Article  CAS  PubMed  Google Scholar 

  • The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273(3):199–208

    Article  Google Scholar 

  • United States Department of Health and Human Services Food and Drug Administration (2005) Guidance for industry noncontraceptive estrogen drug products for the treatment of vasomotor symptoms and vulvar and vaginal atrophy symptoms – recommended prescribing information for health care providers and patient labeling. Draft guidelines. Revision 4. http://www.fda.gov/cder/guidance/6932dft.pdf. Accessed January 2009

  • Vandenbroucke JP (2004) When are observational studies as credible as randomised trials? Lancet 363(9422):1728–1731

    Article  PubMed  Google Scholar 

  • Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321–333

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT, 0200, Australia

    Emily Banks

Authors
  1. Emily Banks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emily Banks .

Editor information

Editors and Affiliations

  1. Dean’s Department, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

    Mira Harrison-Woolrych

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Banks, E. (2015). Menopausal Hormone Therapy: A Safety Perspective. In: Harrison-Woolrych, M. (eds) Medicines For Women. Adis, Cham. https://doi.org/10.1007/978-3-319-12406-3_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-12406-3_11

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-12405-6

  • Online ISBN: 978-3-319-12406-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation